GlaxoSmithKline has unveiled a plan to launch 13 blockbusters between 2022 and 2026, with novel HIV and immuno-oncology therapies at the heart of this ambition.
The goal was unveiled last week by GSK’s chief scientific officer and president of R&D Hal Barron at the virtual J.P. Morgan healthcare conference, where investors were looking for progress...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?